OncoGenex Pharmaceuticals : Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for…

… prostate cancer (mCRPC). In addition, these data presented at the 2015 European Cancer … to alter tumor dynamics by slowing tumor growth and inhibiting tumor resistance to … castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer …